Navigation Links
Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
Date:3/11/2008

Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over

an Interferon-Beta Therapy, According to a New Report from Decision

Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Teva Pharmaceutical's Copaxone has the greatest patient share among first- and second-line therapies, and falls short of Merck Serono/Pfizer's Rebif (by 0.2 percent) in third-line treatment. However, in all three lines of therapy, the interferon-beta drug class (Biogen Idec's Avonex, Rebif, and Berlex's Betaseron) outpaces the altered peptide ligand drug class (consisting only of Copaxone) in patient share. Competition between the two drug classes is fiercest in first-line therapy.

"The low volume of patient share attributed to Avonex or Rebif compared with Copaxone in first- and second-line treatment illustrates a significant delay on the part of physicians and/or patients to engage in an interferon- beta therapy within a year of a patient's initial diagnosis for multiple sclerosis," said Madhuri Borde, analyst at Decision Resources. "However, the magnitudes of Rebif's first- and second-line patient shares suggest that some physicians are treating the disease more aggressively than might be expected, as this high-dose, high-frequency agent reaches patient shares close to and surpassing Avonex in first- and second-line treatment, respectively."

According to the new report entitled Treatment Algorithms in Multiple Sclerosis, neurologists note that Copaxone's better short-term and long-term side-effect/safety profile, together with its lower rate of induction of neutralizing antibodies, are critical reasons for choosing Copaxone instead of Avonex, Rebif and Betaseron. Although Copaxone is administered daily, 23-28 percent of neurologists we surveyed indicate that a key reason to
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 ... Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben zu ... vom Rare Genomics Institute. Biovista unterstützt ... Medikamenten für die Behandlung anderer Krankheiten als denen, ... Steven Laffoon und sein Team bei der ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 waste ... energy process and continue to contribute to the sustainability of our natural resources. ... Energy process has been operating at their Mexico facility, Recicladora Temarry, for the ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... EDISON, N.J. , Sept. 1, 2015  ContraVir ... focused on the development and commercialization of targeted antiviral ... Rodman & Renshaw 17 th Annual Global Investment ... taking place September 8-10, 2015 at The St. Regis ... James Sapirstein , Chief Executive ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... CHAPEL HILL, N.C., March 21, 2011 Although top ... critical in the successful launch of a new product, ... levels of KOL engagement. Consequently, the role of Medical ... leaders has grown dramatically in recent years. ...
... 21, 2011 ICAP Ocean Tomo will ... nebulizer on March 31st at the ICAP Ocean Tomo ... technology of this patent portfolio provides improvements to existing ... Recent technological advancements have triggered the use of ...
... 21, 2011 Peter M. DeComo, Chairman of the ... (PLSG), the organization providing capital investments and customized company ... sciences enterprises, today congratulated John W. Manzetti and the ... 2011 Outstanding Leadership in Technology category winner at ...
Cached Biology Technology:Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 2ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 3ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 4John W. Manzetti and the Pittsburgh Life Sciences Greenhouse Recognized as 2011 Outstanding Leader in Technology 2
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/10/2015)... , August 10, 2015 The latest ... offers comprehensive analysis of the global border security market ... revenues of $16.4bn in 2015. Now: Border security ... an example of the business critical issue you need to ... visiongain ,s objective analysis of how this will impact ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... identified the role of transforming growth hormone factor-Beta (TGF-Beta) ... lung, has been selected to receive the inaugural AACR ... spent more than two decades defining how TGF-Beta affects ... of TGF-Beta receptors led to the spread of cancer ...
... a Brown University scientist, and graduate student Adrian Nestor ... dozens of faces. They determined that men tend to ... common for women. The finding has important implications ... face perception. But the information also has a ...
... ARBOR, Mich.---Scientists have identified 12 new genes that are ... levels, others link melatonin and sleep patterns to small ... risk of diabetes. While these associations are ... and some of them could help explain conditions that ...
Cached Biology News:Men are red, women are green, Brown researcher finds 2Men are red, women are green, Brown researcher finds 3New genes present drug targets for managing cholesterol and glucose levels 2New genes present drug targets for managing cholesterol and glucose levels 3
... The PROTEAN II xi multi-cell is for ... with efficient cooling capabilities. The PROTEAN II xi ... length, comb, type of glass plates, and cooling ... be converted to the PROTEAN II XL multi-cell ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... Cell permeable fluorescent minor groove-binding probe for ... double-stranded DNA (preferentially to AT rich DNA), ... 20 times greater than DAPI alone. DAPI ... bromide for staining DNA in agarose gels. ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: